Circulating amino acid levels and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition and UK Biobank cohorts.

Humans Amino Acids Glutamine Histidine Biological Specimen Banks Prospective Studies Colorectal Neoplasms / epidemiology United Kingdom / epidemiology
Amino acids Colorectal cancer Glutamine Histidine

Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
28 02 2023
Historique:
received: 08 11 2022
accepted: 16 01 2023
entrez: 1 3 2023
pubmed: 2 3 2023
medline: 3 3 2023
Statut: epublish

Résumé

Amino acid metabolism is dysregulated in colorectal cancer patients; however, it is not clear whether pre-diagnostic levels of amino acids are associated with subsequent risk of colorectal cancer. We investigated circulating levels of amino acids in relation to colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) and UK Biobank cohorts. Concentrations of 13-21 amino acids were determined in baseline fasting plasma or serum samples in 654 incident colorectal cancer cases and 654 matched controls in EPIC. Amino acids associated with colorectal cancer risk following adjustment for the false discovery rate (FDR) were then tested for associations in the UK Biobank, for which measurements of 9 amino acids were available in 111,323 participants, of which 1221 were incident colorectal cancer cases. Histidine levels were inversely associated with colorectal cancer risk in EPIC (odds ratio [OR] 0.80 per standard deviation [SD], 95% confidence interval [CI] 0.69-0.92, FDR P-value=0.03) and in UK Biobank (HR 0.93 per SD, 95% CI 0.87-0.99, P-value=0.03). Glutamine levels were borderline inversely associated with colorectal cancer risk in EPIC (OR 0.85 per SD, 95% CI 0.75-0.97, FDR P-value=0.08) and similarly in UK Biobank (HR 0.95, 95% CI 0.89-1.01, P=0.09) In both cohorts, associations changed only minimally when cases diagnosed within 2 or 5 years of follow-up were excluded. Higher circulating levels of histidine were associated with a lower risk of colorectal cancer in two large prospective cohorts. Further research to ascertain the role of histidine metabolism and potentially that of glutamine in colorectal cancer development is warranted.

Sections du résumé

BACKGROUND
Amino acid metabolism is dysregulated in colorectal cancer patients; however, it is not clear whether pre-diagnostic levels of amino acids are associated with subsequent risk of colorectal cancer. We investigated circulating levels of amino acids in relation to colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) and UK Biobank cohorts.
METHODS
Concentrations of 13-21 amino acids were determined in baseline fasting plasma or serum samples in 654 incident colorectal cancer cases and 654 matched controls in EPIC. Amino acids associated with colorectal cancer risk following adjustment for the false discovery rate (FDR) were then tested for associations in the UK Biobank, for which measurements of 9 amino acids were available in 111,323 participants, of which 1221 were incident colorectal cancer cases.
RESULTS
Histidine levels were inversely associated with colorectal cancer risk in EPIC (odds ratio [OR] 0.80 per standard deviation [SD], 95% confidence interval [CI] 0.69-0.92, FDR P-value=0.03) and in UK Biobank (HR 0.93 per SD, 95% CI 0.87-0.99, P-value=0.03). Glutamine levels were borderline inversely associated with colorectal cancer risk in EPIC (OR 0.85 per SD, 95% CI 0.75-0.97, FDR P-value=0.08) and similarly in UK Biobank (HR 0.95, 95% CI 0.89-1.01, P=0.09) In both cohorts, associations changed only minimally when cases diagnosed within 2 or 5 years of follow-up were excluded.
CONCLUSIONS
Higher circulating levels of histidine were associated with a lower risk of colorectal cancer in two large prospective cohorts. Further research to ascertain the role of histidine metabolism and potentially that of glutamine in colorectal cancer development is warranted.

Identifiants

DOI: 10.1186/s12916-023-02739-4 PMID: 36855092 PMC: PMC9976469
pubmed: 36855092
doi: 10.1186/s12916-023-02739-4
pii: 10.1186/s12916-023-02739-4
pmc: PMC9976469
doi:

Substances chimiques

Amino Acids 0
Glutamine 0RH81L854J
Histidine 4QD397987E

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

80

Subventions

Organisme : Cancer Research UK
ID : 21351
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 25004
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209–49.
pubmed: 33538338
Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet. 2005;365(9454):153–65.
pubmed: 15639298 doi: 10.1016/S0140-6736(05)17706-X
Abar L, Vieira AR, Aune D, Sobiecki JG, Vingeliene S, Polemiti E, et al. Height and body fatness and colorectal cancer risk: an update of the WCRF-AICR systematic review of published prospective studies. Eur J Nutr. 2018;57(5):1701–20.
pubmed: 29080978 doi: 10.1007/s00394-017-1557-1
Park JY, Dahm CC, Keogh RH, Mitrou PN, Cairns BJ, Greenwood DC, et al. Alcohol intake and risk of colorectal cancer: results from the UK Dietary Cohort Consortium. Br J Cancer. 2010;103(5):747–56.
pubmed: 20648013 pmcid: 2938250 doi: 10.1038/sj.bjc.6605802
Tabung FK, Brown LS, Fung TT. Dietary Patterns and Colorectal Cancer Risk: a Review of 17 Years of Evidence (2000-2016). Curr Colorectal Cancer Rep. 2017;13(6):440–54.
pubmed: 29399003 pmcid: 5794031 doi: 10.1007/s11888-017-0390-5
Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007;132(6):2208–25.
pubmed: 17498513 doi: 10.1053/j.gastro.2007.03.050
Gunter MJ, Alhomoud S, Arnold M, Brenner H, Burn J, Casey G, et al. Meeting report from the joint IARC–NCI international cancer seminar series: a focus on colorectal cancer. Ann Oncol. 2019;30(4):510–9.
pubmed: 30721924 pmcid: 6503626 doi: 10.1093/annonc/mdz044
Murphy N, Song M, Papadimitriou N, Carreras-Torres R, Langenberg C, Martin RM, et al. Associations Between Glycemic Traits and Colorectal Cancer: A Mendelian Randomization Analysis. J Natl Cancer Inst. 2022;114(5):740–52.
pubmed: 35048991 pmcid: 9086764 doi: 10.1093/jnci/djac011
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and Cancer A consensus report. Diabetes Care. 2010;33(7):1674–85.
pubmed: 20587728 pmcid: 2890380 doi: 10.2337/dc10-0666
Lieu EL, Nguyen T, Rhyne S, Kim J. Amino acids in cancer. Exp Mol Med. 2020;52(1):15–30.
pubmed: 31980738 pmcid: 7000687 doi: 10.1038/s12276-020-0375-3
Goveia J, Pircher A, Conradi L-C, Kalucka J, Lagani V, Dewerchin M, et al. Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities. EMBO Mol Med. 2016;8(10):1134–42.
pubmed: 27601137 pmcid: 5048364 doi: 10.15252/emmm.201606798
Geijsen A, van Roekel EH, van Duijnhoven FJB, Achaintre D, Bachleitner-Hofmann T, Baierl A, et al. Plasma metabolites associated with colorectal cancer stage: Findings from an international consortium. Int J Cancer. 2019;146(12):3256.
pubmed: 31495913 pmcid: 7216900 doi: 10.1002/ijc.32666
Sirniö P, Väyrynen JP, Klintrup K, Mäkelä J, Karhu T, Herzig K-H, et al. Alterations in serum amino-acid profile in the progression of colorectal cancer: associations with systemic inflammation, tumour stage and patient survival. Br J Cancer. 2019;120(2):238–46.
pubmed: 30563990 doi: 10.1038/s41416-018-0357-6
Geijsen A, Brezina S, Keski-Rahkonen P, Baierl A, Bachleitner-Hofmann T, Bergmann MM, et al. Plasma metabolites associated with colorectal cancer: A discovery-replication strategy. Int J Cancer. 2019;145(5):1221–31.
pubmed: 30665271 pmcid: 6614008 doi: 10.1002/ijc.32146
Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, Kibi M, Izumi Y, et al. A Novel Serum Metabolomics-Based Diagnostic Approach for Colorectal Cancer. PLoS One. 2012;7(7):110.
doi: 10.1371/journal.pone.0040459
Nishiumi S, Kobayashi T, Kawana S, Unno Y, Sakai T, Okamoto K, et al. Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry. Oncotarget. 2017;8(10):17115–26.
pubmed: 28179577 pmcid: 5370027 doi: 10.18632/oncotarget.15081
Tan BB, Qiu YP, Zou X, Chen TL, Xie GX, Cheng Y, et al. Metabonomics Identifies Serum Metabolite Markers of Colorectal Cancer. J Proteome Res. 2013;12(6):3000–9.
pubmed: 23675754 pmcid: 5902797 doi: 10.1021/pr400337b
Erben V, Bhardwaj M, Schrotz-King P, Brenner H. Metabolomics Biomarkers for Detection of Colorectal Neoplasms: A Systematic Review. Cancers. 2018;10(8):246.
pubmed: 30060469 pmcid: 6116151 doi: 10.3390/cancers10080246
McCullough ML, Hodge RA, Campbell PT, Stevens VL, Wang Y. Pre-Diagnostic Circulating Metabolites and Colorectal Cancer Risk in the Cancer Prevention Study-II Nutrition Cohort. Metabolites. 2021;11(3):156.
pubmed: 33803340 pmcid: 8000483 doi: 10.3390/metabo11030156
Shu X, Xiang YB, Rothman N, Yu DX, Li HL, Yang G, et al. Prospective study of blood metabolites associated with colorectal cancer risk. Int J Cancer. 2018;143(3):527–34.
pubmed: 29479691 pmcid: 6019169 doi: 10.1002/ijc.31341
Papadimitriou N, Gunter MJ, Murphy N, Gicquiau A, Achaintre D, Brezina S, et al. Circulating tryptophan metabolites and risk of colon cancer: Results from case-control and prospective cohort studies. Int J Cancer. 2021;149(9):1659–69.
pubmed: 34196970 pmcid: 8429124 doi: 10.1002/ijc.33725
Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6b):1113–24.
pubmed: 12639222 doi: 10.1079/PHN2002394
Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol. 1997;26(Suppl 1):S6–14.
pubmed: 9126529 doi: 10.1093/ije/26.suppl_1.S6
Allen N, Sudlow C, Downey P, Peakman T, Danesh J, Elliott P, et al. UK Biobank: Current status and what it means for epidemiology. Health Policy Technol. 2012;1(3):123–6.
doi: 10.1016/j.hlpt.2012.07.003
Romisch-Margl W, Prehn C, Bogumil R, Rohring C, Suhre K, Adamski J. Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics. Metabolomics. 2012;8(1):133–42.
doi: 10.1007/s11306-011-0293-4
Rothwell JA, Murphy N, Besevic J, Kliemann N, Jenab M, Ferrari P, et al. Metabolic Signatures of Healthy Lifestyle Patterns and Colorectal Cancer Risk in a European Cohort. Clin Gastroenterol Hepatol. 2022;20(5):e1061–82.
pubmed: 33279777 pmcid: 9049188 doi: 10.1016/j.cgh.2020.11.045
Stepien M, Duarte-Salles T, Fedirko V, Floegel A, Barupal DK, Rinaldi S, et al. Alteration of amino acid and biogenic amine metabolism in hepatobiliary cancers: Findings from a prospective cohort study. Int J Cancer. 2016;138(2):348–60.
pubmed: 26238458 doi: 10.1002/ijc.29718
Gu JP, Xiao YQ, Shu D, Liang XR, Hu XM, Xie YY, et al. Metabolomics Analysis in Serum from Patients with Colorectal Polyp and Colorectal Cancer by H-1-NMR Spectrometry. Dis Markers. 2019;2019:3491852.
pubmed: 31089393 pmcid: 6476004 doi: 10.1155/2019/3491852
Uchiyama K, Yagi N, Mizushima K, Higashimura Y, Hirai Y, Okayama T, et al. Serum metabolomics analysis for early detection of colorectal cancer. J Gastroenterol. 2017;52(6):677–94.
pubmed: 27650200 doi: 10.1007/s00535-016-1261-6
Li JK, Li J, Wang H, Qi LW, Zhu YM, Lai MD. Tyrosine and Glutamine-Leucine Are Metabolic Markers of Early-Stage Colorectal Cancers. Gastroenterology. 2019;157(1):257.
pubmed: 30885779 doi: 10.1053/j.gastro.2019.03.020
Kuhn T, Floegel A, Sookthai D, Johnson T, Rolle-Kampczyk U, Otto W, et al. Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study. BMC Med. 2016;14:13. https://doi.org/10.1186/s12916-016-0552-3 .
doi: 10.1186/s12916-016-0552-3 pubmed: 26817443 pmcid: 4730724
Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy. 2009;39(12):1786–800.
pubmed: 20085595 doi: 10.1111/j.1365-2222.2009.03374.x
Smolinska S, Jutel M, Crameri R, O'Mahony L. Histamine and gut mucosal immune regulation. Allergy. 2014;69(3):273–81.
pubmed: 24286351 doi: 10.1111/all.12330
Cianchi F, Cortesini C, Schiavone N, Perna F, Magnelli L, Fanti E, et al. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res. 2005;11(19 Pt 1):6807–15.
pubmed: 16203768 doi: 10.1158/1078-0432.CCR-05-0675
Feng RN, Niu YC, Sun XW, Li Q, Zhao C, Wang C, et al. Histidine supplementation improves insulin resistance through suppressed inflammation in obese women with the metabolic syndrome: a randomised controlled trial. Diabetologia. 2013;56(5):985–94.
pubmed: 23361591 doi: 10.1007/s00125-013-2839-7
Jobard E, Dossus L, Baglietto L, Fornili M, Lecuyer L, Mancini FR, et al. Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: a case-control study nested within the French E3N cohort. Br J Cancer. 2021;124(10):1734–43.
pubmed: 33723391 pmcid: 8110540 doi: 10.1038/s41416-021-01304-1
Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine Metabolism in Cancer: Understanding the Heterogeneity. Trends Cancer. 2017;3(3):169–80.
pubmed: 28393116 pmcid: 5383348 doi: 10.1016/j.trecan.2017.01.005
Zhao YQ, Zhao X, Chen V, Feng Y, Wang L, Croniger C, et al. Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo. Sci Rep. 2019;9(1):19180.
pubmed: 31844152 pmcid: 6915720 doi: 10.1038/s41598-019-55718-2
Ling HH, Pan Y-P, Fan C-W, Tseng W-K, Huang J-S, Wu T-H, et al. Clinical Significance of Serum Glutamine Level in Patients with Colorectal Cancer. Nutrients. 2019;11(4):898.
pubmed: 31010101 pmcid: 6521237 doi: 10.3390/nu11040898
Liu XR, Zheng Y, Guasch-Ferre M, Ruiz-Canela M, Toledo E, Clish C, et al. High plasma glutamate and low glutamine-to-glutamate ratio are associated with type 2 diabetes: Case-cohort study within the PREDIMED trial. Nutr Metab Cardiovasc Dis. 2019;29(10):1040–9.
pubmed: 31377179 pmcid: 9257877 doi: 10.1016/j.numecd.2019.06.005
Morze J, Wittenbecher C, Schwingshackl L, Danielewicz A, Rynkiewicz A, Hu FB, et al. Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. Diabetes Care. 2022;45(4):1013–24.
pubmed: 35349649 pmcid: 9016744 doi: 10.2337/dc21-1705
Watson KM, Gaulke CA, Tsikitis VL. Understanding the microbiome: a primer on the role of the microbiome in colorectal neoplasia. Ann Gastroenterol. 2020;33(3):223–36.
pubmed: 32382225 pmcid: 7196612
Mardinoglu A, Shoaie S, Bergentall M, Ghaffari P, Zhang C, Larsson E, et al. The gut microbiota modulates host amino acid and glutathione metabolism in mice. Mol Syst Biol. 2015;11(10):834.
pubmed: 26475342 pmcid: 4631205 doi: 10.15252/msb.20156487
Salahshouri P, Emadi-Baygi M, Jalili M, Khan FM, Wolkenhauer O, Salehzadeh-Yazdi A. A Metabolic Model of Intestinal Secretions: The Link between Human Microbiota and Colorectal Cancer Progression. Metabolites. 2021;11(7):456.
pubmed: 34357350 pmcid: 8303431 doi: 10.3390/metabo11070456
Gao C, Major A, Rendon D, Lugo M, Jackson V, Shi Z, et al. Histamine H2 Receptor-Mediated Suppression of Intestinal Inflammation by Probiotic Lactobacillus reuteri. MBIO. 2015;6(6):e01358.
pubmed: 26670383 pmcid: 4701830 doi: 10.1128/mBio.01358-15
Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BAH, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 2016;535(7612):376.
pubmed: 27409811 doi: 10.1038/nature18646
Iguacel I, Schmidt JA, Perez-Cornago A, Van Puyvelde H, Travis R, Stepien M, et al. Associations between dietary amino acid intakes and blood concentration levels. Clin Nutr. 2021;40(6):3772–9.
pubmed: 34130023 doi: 10.1016/j.clnu.2021.04.036
Breier M, Wahl S, Prehn C, Fugmann M, Ferrari U, Weise M, et al. Targeted Metabolomics Identifies Reliable and Stable Metabolites in Human Serum and Plasma Samples. PLoS One. 2014;9(2):e89728.
pubmed: 24586991 pmcid: 3933650 doi: 10.1371/journal.pone.0089728

Auteurs

Joseph A Rothwell (JA)

Centre for Epidemiology and Population Health (Inserm U1018), Exposome and Heredity team, Faculté de Médecine, Université Paris-Saclay, UVSQ, Gustave Roussy, F-94805, Villejuif, France. joseph.rothwell@inserm.fr.
ORCID: 0000-0002-6927-3360

Jelena Bešević (J)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Niki Dimou (N)

International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.

Marie Breeur (M)

International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.

Neil Murphy (N)

International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.

Mazda Jenab (M)

International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.

Roland Wedekind (R)

International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.

Vivian Viallon (V)

International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.

Pietro Ferrari (P)

International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.

David Achaintre (D)

International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.

Audrey Gicquiau (A)

International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.

Sabina Rinaldi (S)

International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.

Augustin Scalbert (A)

International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.

Inge Huybrechts (I)

International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.

Cornelia Prehn (C)

Metabolomics and Proteomics Core, Helmholtz Zentrum München, 85764, Neuherberg, Germany.

Jerzy Adamski (J)

Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 8 Medical Drive, Singapore, 117597, Singapore.
Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.
Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000, Ljubljana, Slovenia.

Amanda J Cross (AJ)

School of Public Health, Imperial College London, London, UK.

Hector Keun (H)

Department of Surgery & Cancer, Imperial College London, London, UK.

Marc Chadeau-Hyam (M)

School of Public Health, Imperial College London, London, UK.

Marie-Christine Boutron-Ruault (MC)

Centre for Epidemiology and Population Health (Inserm U1018), Exposome and Heredity team, Faculté de Médecine, Université Paris-Saclay, UVSQ, Gustave Roussy, F-94805, Villejuif, France.

Kim Overvad (K)

Department of Public Health, Aarhus University, Bartholins Allé 2, DK-8000, Aarhus, Denmark.

Christina C Dahm (CC)

Department of Public Health, Aarhus University, Bartholins Allé 2, DK-8000, Aarhus, Denmark.

Therese Haugdahl Nøst (TH)

Faculty of Health Sciences, Department of Community Medicine, UiT the Arctic University of Norway, N-9037, Tromsø, Norway.

Torkjel M Sandanger (TM)

Faculty of Health Sciences, Department of Community Medicine, UiT the Arctic University of Norway, N-9037, Tromsø, Norway.

Guri Skeie (G)

Faculty of Health Sciences, Department of Community Medicine, UiT the Arctic University of Norway, N-9037, Tromsø, Norway.

Raul Zamora-Ros (R)

Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

Kostas K Tsilidis (KK)

School of Public Health, Imperial College London, London, UK.
Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.

Fabian Eichelmann (F)

German Center for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.

Matthias B Schulze (MB)

Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.

Bethany van Guelpen (B)

Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden.
Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden.

Linda Vidman (L)

Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden.

Maria-José Sánchez (MJ)

Escuela Andaluza de Salud Pública (EASP), 18011, Granada, Spain.
Instituto de Investigación Biosanitaria ibs. GRANADA, 18012, Granada, Spain.
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain.
Department of Preventive Medicine and Public Health, University of Granada, 18071, Granada, Spain.

Pilar Amiano (P)

Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Spain.
Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastián, Spain.
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.

Eva Ardanaz (E)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain.
Navarra Public Health Institute, Leyre 15, 31003, Pamplona, Spain.
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.

Karl Smith-Byrne (K)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.

Ruth Travis (R)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Verena Katzke (V)

German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.

Rudolf Kaaks (R)

German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.

Jeroen W G Derksen (JWG)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Sandra Colorado-Yohar (S)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain.
Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia.

Rosario Tumino (R)

Cancer Registry and Histopathology Department, Provincial Health Authority (ASP), Ragusa, Italy.

Bas Bueno-de-Mesquita (B)

Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720, BA, Bilthoven, The Netherlands.

Paolo Vineis (P)

School of Public Health, Imperial College London, London, UK.
Italian Institute of Technology, Genova, Italy.

Domenico Palli (D)

Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy.

Fabrizio Pasanisi (F)

Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.

Anne Kirstine Eriksen (AK)

Danish Cancer Society Research Center, Diet, Genes and Environment, Strandboulevarden 49, DK-2100, Copenhagen, Denmark.
Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

Anne Tjønneland (A)

Danish Cancer Society Research Center, Diet, Genes and Environment, Strandboulevarden 49, DK-2100, Copenhagen, Denmark.

Gianluca Severi (G)

Centre for Epidemiology and Population Health (Inserm U1018), Exposome and Heredity team, Faculté de Médecine, Université Paris-Saclay, UVSQ, Gustave Roussy, F-94805, Villejuif, France.
Department of Statistics, Computer Science, Applications "G. Parenti" University of Florence, Florence, Italy.

Marc J Gunter (MJ)

International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69008, Lyon, France.
School of Public Health, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Circulating amino acid levels and colorectal...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Circulating amino acid levels and colorectal...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés neutres › Glutamine › Circulating amino acid levels and colorectal...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés essentiels › Histidine › Circulating amino acid levels and colorectal...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Établissements de santé › Biobanques › Circulating amino acid levels and colorectal...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Circulating amino acid levels and colorectal...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du rectum › Tumeurs colorectales › Circulating amino acid levels and colorectal...
questionsmedicales.fr › Régions géographiques › Europe › Royaume-Uni › Circulating amino acid levels and colorectal...